Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/24825
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Mechanisms of endothelial cell protection by blockade of the JAK2 pathway

AutorNeria, Fernando; Peinado, Héctor; Cano, Amparo CSIC; Castilla, María Ángeles CSIC
Palabras claveJAK2/STAT
Cytoprotection
Anoikis
AG490
Fecha de publicaciónmar-2007
EditorAmerican Heart Association
CitaciónArteriosclerosis Thrombosis and Vascular Biology 292(3): C1123-C1131 (2007)
ResumenInhibition of the JAK2/STAT pathway has been implicated recently in cytoprotective mechanisms in both vascular smooth muscle cells and astrocytes. The advent of JAK2-specific inhibitors provides a practical tool for the study of this pathway in different cellular types. An interest in finding methods to improve endothelial cell (EC) resistance to injury led us to examine the effect of JAK2/STAT inhibition on EC protection. Furthermore, the signaling pathways involved in JAK2/STAT inhibition-related actions were examined. Our results reveal, for the first time, that blockade of JAK2 with the tyrosine kinase inhibitor AG490 strongly protects cultured EC against cell detachment-dependent death and serum deprivation and increases reseeding efficiency. Confirmation of the specificity of the effects of JAK2 inhibition was attained by finding protective effects on transfection with a dominant negative JAK2. Furthermore, AG490 blocked serum deprivation-induced phosphorylation of JAK2. In terms of mechanism, treatment with AG490 induces several relevant responses, both in monolayer and detached cells. These mechanisms include the following: 1) Increase and nuclear translocation of the active, dephosphorylated form of beta-catenin. In functional terms, this translocation is transcriptionally active, and its protective effect is further supported by the stimulation of EC cytoprotection by transfectionally induced excess of beta-catenin. 2) Increase of platelet endothelial cell adhesion molecule (PECAM)/CD31 levels. 3) Increase in total and phosphorylated AKT. 4) Increase in phosphorylated glycogen synthase kinase (GSK)3alpha/beta. The present findings imply potential practical applications of JAK2 inhibition on EC. These applications affect not only EC in the monolayer but also circulating detached cells and involve mechanistic interactions not previously described.
Descripción10 pages, 7 figures.
Versión del editorhttp://dx.doi.org/10.1152/ajpcell.00548.2005
URIhttp://hdl.handle.net/10261/24825
DOI10.1152/ajpcell.00548.2005
ISSN1079-5642
Aparece en las colecciones: (IIBM) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
JAK2 pathway.pdf552,1 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

11
checked on 29-mar-2024

WEB OF SCIENCETM
Citations

10
checked on 29-feb-2024

Page view(s)

382
checked on 18-abr-2024

Download(s)

453
checked on 18-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.